This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (11)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Sexually Transmitted Diseases  • Women's Health, Other  • Alert me on articles by topic

It's Time to Move On

Barbra A. Richardson, PhD

JAMA. 2002;287:1171-1172.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Nonoxynol-9 has been used as a spermicide for more than half a century. The need for a female-controlled method for preventing acquisition of sexually transmitted infections (STIs) led to research into nonoxynol-9 as a vaginal microbicide. By the end of the 1980s, several studies of the in vitro antimicrobial activity of nonoxynol-9 showed that it had the ability to inactivate various sexually transmitted pathogens, including Neisseria gonorrhoeae, Chlamydia trachomatis, and human immunodeficiency virus type 1 (HIV-1).^1-3 Animal studies conducted later seemed to confirm the results observed, suggesting that nonoxynol-9 had high potential as an effective vaginal microbicide for prevention of STIs.^4-6

Given these promising preclinical findings, several randomized clinical trials investigating the effect of intravaginal use of nonoxynol-9 on acquisition of STIs have been conducted and have yielded conflicting results regarding the effectiveness and safety profile of nonoxynol-9.^7-13 Three^7-9 of 6 trials found a . . . [Full Text of this Article]

Author Affiliation: Department of Biostatistics, University of Washington, Seattle.

RELATED ARTICLE

Effect of Nonoxynol-9 Gel on Urogenital Gonorrhea and Chlamydial Infection: A Randomized Controlled Trial
Ronald E. Roddy, Léopold Zekeng, Kelley A. Ryan, Ubald Tamoufé, and Kathryn G. Tweedy
JAMA. 2002;287(9):1117-1122.
ABSTRACT | FULL TEXT